Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer targeting the molecular differences. Blueprint Medicines focuses selective drugs for genomically defined cancer patients.
Website: blueprintmedicines.com



Growth: Good revenue growth rate 55.2%, there is slowdown compared to average historical growth rates 62.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -27.8%. On average the margin is improving steadily. Gross margin is high, +98.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.08 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 241.0% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 76.0% overvalued

Key Financials (Download financials)

Ticker: BPMC
Share price, USD:  (0.0%)129.46
year average price 118.08  


year start price 95.19 2025-02-13

min close price 79.22 2025-04-08

max close price 129.46 2025-07-17

current price 129.46 2026-02-12
Common stocks: 59 570 497

Dividend Yield:  0.0%
EV / Sales: 13.6x
Margin (EBITDA LTM / Revenue): -27.8%
Fundamental value created in LTM:
Market Cap ($m): 7 712
Net Debt ($m): -110
EV (Enterprise Value): 7 602
Price to Book: 22.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-09-15businesswire.com

Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

2025-08-27businesswire.com

Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

2025-07-14globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)

2025-06-12prnewswire.com

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

2025-06-02globenewswire.com

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

2025-06-02barrons.com

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

2025-05-01seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

2025-04-07seekingalpha.com

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

2025-02-14zacks.com

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

2025-02-13seekingalpha.com

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 149M 509M 128M 138M 96M 249M 57M 58M 63M 204M 66M 180M 794M
costOfRevenue 3M 20M 2M 11M 8M 13M 5M 2M 3M 18M 3M 18M 425 000
grossProfit 147M 489M 126M 127M 88M 237M 52M 55M 60M 186M 63M 162M 793M
grossProfitRatio 0.981 0.985 0.919 0.917 0.92 0.96 0.95 0.955
researchAndDevelopmentExpenses 92M 341M 85M 81M 83M 428M 110M 110M 112M 477M 128M 601M 327M
generalAndAdministrativeExpenses 0 263M 63M 67M 67M 278M 58M 53M 0 219M 0 182M 148M
sellingAndMarketingExpenses 0 97M 27M 23M 17M 17M 13M 19M 0 18M 0 14M 9M
sellingGeneralAndAdministrativeExpenses 96M 359M 90M 89M 84M 295M 71M 72M 71M 237M 58M 195M 158M
otherExpenses 0 0 0 -1000 376 000 0 -728 000 -626 000 1M 9M 2M 8M -366 000
operatingExpenses 188M 701M 175M 170M 167M 723M 181M 183M 184M 724M 187M 804M 485M
costAndExpenses 190M 721M 177M 181M 175M 736M 186M 186M 187M 742M 190M 822M 485M
interestIncome 0 41M 11M 10M 9M 33M 9M 8M 0 0 0 2M 7M
interestExpense 8M 69M 19M 17M 15M 52M -4M -4M 6M 17M -8M 0 0
depreciationAndAmortization -34M 16M 4M 4M 5M 12M 3M 4M 12M 20M 2M 13M 12M
ebitda -41M 19M -33M -29M -74M -470M -129M -128M -123M -515M -123M -628M 309M
ebitdaratio -0.275 -0.26 -0.285 -0.77 -2.28 -2.223 -1.947 -1.859
operatingIncome -41M -212M -49M -43M -79M -486M -129M -128M -135M -549M -124M -648M 302M
operatingIncomeRatio -0.275 -0.382 -0.312 -0.82 -2.28 -2.223 -2.139 -1.884
totalOtherIncomeExpensesNet 42M 146M -7M -7M 168M -20M -5M -626 000 6M -15M -8M 897 000 6M
incomeBeforeTax 1M -66M -56M -50M 89M -506M -134M -133M -129M -552M -132M -641M 315M
incomeBeforeTaxRatio 0.009 -0.437 -0.361 0.929 -2.36 -2.303 -2.039 -2.005
incomeTaxExpense 789 000 1M 273 000 102 000 180 000 968 000 197 000 190 000 520 000 5M 886 000 3M 1M
netIncome 496 000 -67M -56M -50M 89M -507M -134M -133M -130M -558M -133M -644M 314M
netIncomeRatio 0.003 -0.439 -0.362 0.927 -2.364 -2.307 -2.047 -2.018
eps 0.01 -1.07 -0.89 -0.8 1.45 -8.37 -2.2 -2.19 -2.15 -9.35 -2.23 -11.01 5.76
epsdiluted 0.01 -0.89 -0.8 1.4 -2.2 -2.19 -2.15 -2.23
weightedAverageShsOut 64M 63M 63M 63M 62M 61M 61M 61M 60M 60M 60M 59M 55M
weightedAverageShsOutDil 64M 63M 63M 63M 64M 61M 61M 61M 60M 60M 60M 59M 56M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -28M -19M -17M 2M 7M
ebit 3M -482M -529M -641M 315M
nonOperatingIncomeExcludingInterest -215M -4M -9M -897 000 -6M
netIncomeFromContinuingOperations -67M -507M -558M -644M 314M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -67M -507M -558M -644M 314M
epsDiluted -1.07 -8.37 -9.35 -11.01 5.59

Balance Sheet Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 122M 102M 89M 55M 113M 71M 56M 76M 170M 120M 291M 210M 685M
shortTermInvestments 454M 513M 645M 709M 535M 639M 657M 647M 652M 825M 846M 267M 187M
cashAndShortTermInvestments 576M 615M 734M 764M 648M 711M 827M 837M 961M 1 078M 1 137M 1 035M 1 550M
netReceivables 80M 78M 66M 85M 60M 43M 41M 38M 31M 37M 22M 37M 25M
inventory 13M 14M 13M 15M 31M 21M 16M 17M 18M 30M 35M 22M 9M
otherCurrentAssets 33M 36M 42M 40M 38M 33M 37M 33M 731M 35M 34M 0 0
totalCurrentAssets 702M 743M 855M 904M 777M 808M 808M 811M 900M 1 047M 1 228M 554M 928M
propertyPlantEquipmentNet 98M 101M 104M 109M 113M 116M 116M 114M 113M 115M 117M 121M 102M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 277M 0 143M 126M 84M 142M 142M 167M 161M 83M 558M 678M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 396M 59M 241M 48M 23M 41M 39M 39M 40M 27M 30M 20M 11M
totalNonCurrentAssets 494M 437M 345M 300M 262M 241M 297M 295M 320M 303M 231M 698M 791M
otherAssets 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 1 196M 1 180M 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M 1 252M 1 718M
accountPayables 800 000 7M 5M 5M 5M 5M 7M 7M 11M 3M 4M 8M 4M
shortTermDebt 58M 44M 58M 127M 87M 69M 42M 29M 28M 17M 25M 8M 8M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 64M 64M 4M 7M 812 000 448M 446M 443M 449M 25M 37M 13M
otherCurrentLiabilities 190M 80M 131M 108M 107M 61M -300M -313M -309M 31M 121M 85M 70M
totalCurrentLiabilities 251M 261M 258M 244M 207M 215M 197M 169M 173M 183M 176M 150M 131M
longTermDebt 65M 343M 413M 626M 432M 611M 84M 87M 90M 122M 219M 0 0
deferredRevenueNonCurrent 0 202M 8M 8M 5M 5M 5M 5M 5M 427M 415M 25M 41M
deferredTaxLiabilitiesNonCurrent 0 0 0 75M 78M 0 0 0 0 0 0 0 -13M
otherNonCurrentLiabilities 538M 7M 207M 6M 6M 6M 616M 534M 538M 437M 588M 3M 7M
totalNonCurrentLiabilities 603M 620M 629M 640M 521M 704M 705M 626M 633M 652M 643M 132M 118M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 82M 85M 88M 78M 94M 96M 98M 101M 103M 106M 111M 90M
totalLiabilities 853M 881M 887M 883M 728M 919M 903M 795M 806M 835M 818M 281M 248M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 65 000 64 000 63 000 63 000 63 000 61 000 61 000 61 000 60 000 60 000 60 000 59 000 58 000
retainedEarnings -2 407M -2 407M -2 357M -2 301M -2 251M -2 340M -2 229M -2 095M -1 963M -1 833M -1 674M -1 275M -631M
accumulatedOtherComprehensiveIncomeLoss -3M -4M -1M -4M -4M -3M -3M -4M -5M -10M -15M -4M -5M
othertotalStockholdersEquity 2 752M 2 671M 2 625M 2 565M 2 434M 2 411M 2 381M 2 329M
totalStockholdersEquity 342M 299M 313M 320M 311M 131M 203M 311M 414M 515M 640M 971M 1 470M
totalEquity 342M 299M 313M 320M 311M 131M 203M 311M 414M 515M 640M 971M 1 470M
totalLiabilitiesAndStockholdersEquity 1 196M 1 200M 1 204M 1 038M 1 105M 1 106M 1 220M 1 458M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 196M 1 180M 1 200M 1 204M 1 038M 1 049M 1 105M 1 106M 1 220M 1 350M 1 458M 1 252M 1 718M
totalInvestments 454M 791M 645M 852M 661M 724M 657M 647M 652M 959M 929M 825M 865M
totalDebt 123M 469M 471M 740M 598M 774M 126M 116M 118M 242M 244M 111M 90M
netDebt 504 000 367M 382M 686M 485M 703M 70M 41M -52M 123M -47M -99M -595M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 76M 43M 24M 25M 7M
otherReceivables 2M 351 000 13M 12M 18M
prepaids 0 0 0 18M 22M
totalPayables 7M 5M 3M 8M 4M
otherPayables 0 0 0 0 0
accruedExpenses 54M 67M 122M 29M 28M
capitalLeaseObligationsCurrent 13M 12M 11M 8M 8M
capitalLeaseObligationsNonCurrent 69M 82M 93M 103M 82M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 709M 2 474M 2 358M 2 250M 2 107M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC BPMC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-01 2024-10-30 2024-08-01 2024-05-02 2023-10-26 2023-08-02 2023-05-04 2022-11-01
acceptedDate 2025-05-01 16:19:40 2025-02-13 17:09:26 2024-10-30 16:27:49 2024-08-01 16:48:17 2024-05-02 16:43:51 2024-02-15 17:26:31 2023-10-26 16:01:57 2023-08-02 16:02:22 2023-05-04 16:23:29 2023-02-16 17:24:10 2022-11-01 16:18:43 2022-02-17 08:18:57 2021-02-17 16:37:42
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 496 000 -67M -56M -50M 89M -507M -134M -133M -130M -558M -133M -644M 314M
depreciationAndAmortization 1M 16M 4M 4M 5M 12M 3M 4M 4M 12M 2M 6M 7M
deferredIncomeTax 0 0 0 0 0 0 -12M 0 0 0 0 1M 466 000
stockBasedCompensation 29M 109M 28M 28M 24M 93M 23M 24M 23M 99M 24M 92M 76M
changeInWorkingCapital 0 0 15M -27M -43M -41M 3M -28M -26M -54M -6M -24M -16M
accountsReceivables -1M -33M 20M -25M -17M -8M -6M -8M -5M 2M 8M -18M -6M
inventory 187 000 -4M -4M -5M 3M -4M 3M -8M 78 000 -9M -6M -13M -7M
accountsPayables -6M 2M 3M -82 000 313 000 2M 26 000 -4M 8M -6M -9M 4M -791 000
otherWorkingCapital 0 0 -4M 3M -29M -31M 6M -8M -29M -41M 1M 3M -2M
otherNonCashItems -85M -251M -5M -3M -128M 7M 12M 3M 6M -2M -17M 270M 6M
netCashProvidedByOperatingActivities -54M -193M -14M -48M -102M -437M -104M -130M -123M -502M -130M -299M 387M
investmentsInPropertyPlantAndEquipment -2M -5M -25 000 -3M -1M -16M -6M -3M -3M -9M -4M -261M -3M
acquisitionsNet 0 0 0 0 0 0 3M 0 0 0 0 258M 431M
purchasesOfInvestments -283M -966M -201M -355M -200M -766M -241M -275M -133M -490M -219M -655M -969M
salesMaturitiesOfInvestments 350M 924M 231M 170M 278M 1 056M 238M 310M 308M 349M 91M 691M 538M
otherInvestingActivites 0 0 0 78M -3M 0 0 -289 000
netCashUsedForInvestingActivites 65M 30M -188M 77M -10M 32M 173M -132M
debtRepayment 0 0 147M -369 000 -98M 0 0 0
commonStockIssued 0 -99M 31M 67M 431 000 5M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 9M 18M 31M -369 000 196M 0 0 381M
netCashUsedProvidedByFinancingActivities 9M 18M 178M 67M 98M 5M 0 381M
effectOfForexChangesOnCash 661 000 -909 000 591 000 -31 000 -145 000 202 000 -541 000 59 000 197 000 -207 000 -379 000 -888 000 -345 000
netChangeInCash 20M 32M 46M -59M 42M -43M -16M -93M 50M -90M 118M -475M 570M
cashAtEndOfPeriod 134M 114M 101M 55M 113M 82M 66M 82M 175M 125M 297M 215M 690M
cashAtBeginningOfPeriod 114M 82M 55M 113M 71M 125M 82M 175M 125M 215M 179M 690M 120M
operatingCashFlow -54M -193M -14M -48M -102M -437M -104M -130M -123M -502M -130M -299M 387M
capitalExpenditure -2M -5M -25 000 -3M -1M -16M -6M -3M -3M -9M -4M -261M -3M
freeCashFlow -56M -197M -14M -51M -103M -453M -111M -133M -126M -511M -134M -560M 384M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-17 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -290 000 -258M -431M
netCashProvidedByInvestingActivities -48M 274M -150M -226M -434M
netDebtIssuance 147M 98M 138M 0 0
longTermNetDebtIssuance 147M 98M 138M 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 49M 21M 0 0 582M
netCommonStockIssuance 49M 21M 0 0 582M
commonStockIssuance 49M 0 8M 51M 582M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 77M -44 000 424M 51M 35M
netCashProvidedByFinancingActivities 273M 119M 562M 51M 618M
incomeTaxesPaid 1M 0 7M 694 000 778 000
interestPaid 0 38M 10M 0 0

Earning call transcript

2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-06-02 10:13 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-05-01 20:19 ET
Blueprint Medicines reported for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 8
2025-05-01 11:12 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Blueprint Medicines published news for 2025 q1
SEC form 10
2025-02-13 17:09 ET
Blueprint Medicines reported for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 8
2025-02-13 07:34 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2025-02-13 00:00 ET
Blueprint Medicines published news for 2024 q4
SEC form 10
2024-10-30 16:27 ET
Blueprint Medicines reported for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 8
2024-10-30 07:07 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-10-30 00:00 ET
Blueprint Medicines published news for 2024 q3
SEC form 10
2024-08-01 16:48 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines published news for 2024 q2
SEC form 8
2024-08-01 07:29 ET
Blueprint Medicines reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Blueprint Medicines published news for 2024 q2
SEC form 10
2024-05-02 16:43 ET
Blueprint Medicines published news for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines reported for 2024 q1
SEC form 8
2024-05-02 07:09 ET
Blueprint Medicines published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Blueprint Medicines published news for 2024 q1
SEC form 10
2024-02-15 00:00 ET
Blueprint Medicines reported for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Blueprint Medicines published news for 2023 q4
SEC form 10
2023-10-26 16:01 ET
Blueprint Medicines published news for 2023 q3
SEC form 8
2023-10-26 07:00 ET
Blueprint Medicines reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
Blueprint Medicines published news for 2023 q3
SEC form 10
2023-08-02 16:02 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-08-02 07:00 ET
Blueprint Medicines reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Blueprint Medicines published news for 2023 q2
SEC form 6
2023-06-30 06:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-27 16:01 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:07 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:06 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:05 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:04 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:03 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-23 19:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:52 ET
Blueprint Medicines published news for 2023 q1
SEC form 6
2023-06-07 19:48 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Blueprint Medicines published news for 2023 q1
SEC form 8
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
Blueprint Medicines reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Blueprint Medicines reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Blueprint Medicines published news for 2022 q3
SEC form 8
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Blueprint Medicines reported for 2022 q2
SEC form 8
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Blueprint Medicines reported for 2022 q1
SEC form 10
2022-02-17 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
Blueprint Medicines published news for 2021 q4
SEC form 8
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
Blueprint Medicines published news for 2021 q3
SEC form 8
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Blueprint Medicines published news for 2021 q2
SEC form 8
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
Blueprint Medicines published news for 2021 q1